Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of Oncology
|
May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer
Howard Burris, Joe Stephenson, Gregory A Otterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2009
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer
George R Blumenschein, Karen Reckamp, G Joe Stephenson, et al.
Plos One
|
October 15, 2014
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience
Michael B Bass, Bin Yao, Yong-Jiang Hei, et al.
Breast Cancer Research and Treatment
|
August 9, 2012
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
Richard H De Boer, Dusan Kotasek, Shane White, et al.
Frontiers in Cellular and Infection Microbiology
|
April 9, 2026
Emergence of multidrug-resistant ST876 serotype 14 <i>Streptococcus pneumoniae</i> with spontaneous mutations driving pathogenesis: genomic and clinical insights from pneumococcal pericarditis and global screening
Lin Liu, Shouyuan Chen, Tingting Hong, et al.
Chest
|
October 14, 2008
Predictors of habitual snoring and obstructive sleep apnea risk in patients with asthma
Mihaela Teodorescu, Flavia B Consens, William F Bria, et al.
Breast Cancer Research : BCR
|
March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Stephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
The Lancet. Oncology
|
February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of Oncology
|
May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer
Howard Burris, Joe Stephenson, Gregory A Otterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2009
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer
George R Blumenschein, Karen Reckamp, G Joe Stephenson, et al.
Plos One
|
October 15, 2014
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience
Michael B Bass, Bin Yao, Yong-Jiang Hei, et al.
Breast Cancer Research and Treatment
|
August 9, 2012
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
Richard H De Boer, Dusan Kotasek, Shane White, et al.
Frontiers in Cellular and Infection Microbiology
|
April 9, 2026
Emergence of multidrug-resistant ST876 serotype 14 <i>Streptococcus pneumoniae</i> with spontaneous mutations driving pathogenesis: genomic and clinical insights from pneumococcal pericarditis and global screening
Lin Liu, Shouyuan Chen, Tingting Hong, et al.
Chest
|
October 14, 2008
Predictors of habitual snoring and obstructive sleep apnea risk in patients with asthma
Mihaela Teodorescu, Flavia B Consens, William F Bria, et al.
Breast Cancer Research : BCR
|
March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Stephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
The Lancet. Oncology
|
February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Page
of 2